Document Detail

No Association between hOGG1 Ser326Cys Polymorphism and Hepatocellular Carcinoma.
MedLine Citation:
PMID:  23186590     Owner:  NLM     Status:  Publisher    
Background/Aims: To clarify any association between the hOGG1 Ser326Cys polymorphism and susceptibility to hepatocellular carcinoma (HCC). Methodology: The PubMed, CNKI databases were searched for all available articles. The OR corresponding to the 95% confidence interval (95% CI) was used to assess the association between hOGG1 Ser326Cys polymorphism and susceptibility to HCC. Results: Seven case-control studies, with 1,663 cases and 1,675 controls, were available for this analysis. No association was found between hOGG1 Ser326Cys polymorphism and HCC risk (dominant model: OR=0.695, 95% CI: 0.501-0.964, p=0.029; additive model: OR=0.682, 95% CI: 0.374-1.245, p=0.213; recessive model: OR=1.215, 95% CI: 0.711-2.078, p=0.476). Sensitivity analysis did not perturb the results. Conclusions: These findings indicated that hOGG1 Ser326Cys polymorphism may not play a role in HCC development. However, larger scale studies are needed for confirmation.
Tu Zhen-Bo; Feng An-Lin; Li Ling; Zhou Su-Fang
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-28
Journal Detail:
Title:  Hepato-gastroenterology     Volume:  60     ISSN:  0172-6390     ISO Abbreviation:  Hepatogastroenterology     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8007849     Medline TA:  Hepatogastroenterology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Nigerian Twin and Sibling Registry.
Next Document:  The Short-Term Efficacy of Entecavir in Lamivudine-Resistant Chronic Hepatitis B: Influence of Seque...